Three developments in the exoskeleton space have converged in recent months to signal something the industry has been promising and failing to deliver for over a decade: personal exoskeletons are moving from research prototypes to products that people will actually wear.
Wandercraft has begun a pivotal clinical trial for its Personal Exoskeleton at the James J. Peters VA Medical Center in the Bronx—the world’s first self-balancing exoskeleton designed for personal daily use, not just clinical rehabilitation sessions. The French robotics company, backed by $75 million in Series D funding and integrating NVIDIA Omniverse simulation for reinforcement learning, intends to seek FDA clearance immediately following trial completion, with a U.S. launch anticipated in 2026 and expected Medicare coverage.
German Bionic presented its Exia exoskeleton at CES 2026—the world’s most powerful series-production exoskeleton, delivering up to 38 kilograms of dynamic lift support per movement, powered by what the company calls “Augmented AI” trained on billions of real human motion data points.
And the IRMO M1, a consumer-focused lower-body exoskeleton using AI and LADAR sensors to predict terrain, begins global shipping in May 2026 with 45% stride assistance and 60% knee impact reduction—marketed not to patients or industrial workers, but to hikers, travelers, and aging adults who simply want to move better.
The exoskeleton has left the lab. It is entering the clinic, the warehouse, and the trail.
What Took So Long
Exoskeletons have been “five years away” for twenty years. The reasons for the delay are instructive because they illuminate precisely the challenges that current products have finally overcome—partially.
Power. Early exoskeletons carried battery packs that limited operation to 2-4 hours. The Exia achieves full-shift operation through energy-efficient actuator design and regenerative braking during descent movements. The IRMO M1 claims 8+ hours of battery life at moderate assistance levels. These are workable durations, not generous ones.
Weight. An exoskeleton that weighs 25 kilograms and provides 30 kilograms of lift support has a net benefit of 5 kilograms—hardly transformative. The RoboCT GoGo exoskeleton, also shown at CES 2026, weighs 2.3 kilograms. The trend is unmistakable: useful exoskeletons are getting lighter faster than they are getting stronger, which turns out to be the correct engineering priority.
Intelligence. The breakthrough enabling current-generation products is not mechanical—it is computational. Wandercraft’s self-balancing system uses NVIDIA Isaac Sim-trained reinforcement learning models to predict and compensate for the user’s movements in real time. The IRMO M1’s LADAR terrain prediction adjusts assistance profiles before the user’s foot contacts the ground. Ascentiz’s modular system integrates AI trained on 690,000 gait cycles. The exoskeleton is no longer a powered frame. It is a movement partner that anticipates what the body will do next.
Where External Enhancement Stops
These products are impressive within their paradigm. That paradigm has a ceiling.
An exoskeleton is, fundamentally, a machine that the body wears. It applies forces to joints through external contact points—straps, cuffs, rigid frames pressed against skin and bone. The assistance it provides is mediated by the mechanical interface between device and body, and that interface is inherently lossy. Forces transmit imperfectly through soft tissue. Pressure points cause fatigue and injury over extended wear. The device’s model of the body is an approximation, however sophisticated, and the gap between model and reality produces inefficiency, discomfort, and—at the margins—risk.
This is why Unzyme Laboratories pursued a different approach entirely.
The ExoFrame Difference
ExoFrame technology, recently cleared for Paralympic competition in 2028, does not sit outside the body. It integrates with it.
Where external exoskeletons apply force through contact with skin, ExoFrame’s skeletal reinforcement system bonds directly to bone through our biocompatible titanium-polymer matrix. There is no strap. There is no cuff. There is no mechanical interface to introduce loss, discomfort, or pressure injury. The forces are transmitted through the skeleton itself—the same load-bearing structure that evolution designed for exactly this purpose.
Where external exoskeletons use AI to predict the user’s intended movement, ExoFrame reads motor neuron signals directly through integrated neural taps. There is no prediction latency. There is no model approximation error. The system knows what the body intends because it is wired into the neural pathways that generate that intention.
Where external exoskeletons add mass that the body must carry when the device is unpowered, ExoFrame’s reinforced skeletal structure provides passive strength enhancement even without active power. The titanium-polymer matrix increases bone strength and load-bearing capacity as a permanent structural improvement. The body does not carry ExoFrame. ExoFrame is part of the body.
The Market Implication
We do not view Wandercraft, German Bionic, or IRMO as competitors. They are serving a market that Unzyme Laboratories does not target: people who want assistance but are not prepared for integration.
This is a valid market. It may be a large market. There are millions of people with mobility impairments, millions of industrial workers performing repetitive physical labor, millions of aging adults whose joints and muscles are declining faster than their ambitions. External exoskeletons will help these people, and that help has value.
But external enhancement is a transitional technology. It is the hearing aid before the cochlear implant. The wheelchair before ExoFrame. The contact lens before OptiLens Pro. It addresses the symptom—insufficient physical capability—without addressing the cause: a body that was not built for the demands being placed on it.
The personal exoskeleton market that Wandercraft and others are creating will, over the next decade, introduce millions of people to the experience of augmented physical capability. Some of them will be satisfied with strapping on a device each morning and removing it each night. Others will ask the question that leads them to us: Why should I take it off?
We will be ready with the answer.
Erik Lindqvist is Chief Communications Officer at Unzyme Laboratories.
Related:
- ExoFrame Technology Receives Paralympic Clearance — Competition-grade skeletal enhancement approved for 2028 Games
- DermaPlate Armor — Subdermal protective reinforcement
- OptiLens Pro — Integrated ocular enhancement
- AI Prosthetics Approach Natural Movement — The convergence of AI and physical enhancement